Duobrii

Acne Vulgaris, Hypopigmentation, Lentigo + 4 more
Treatment
9 FDA approvals
20 Active Studies for Duobrii

What is Duobrii

TazaroteneThe Generic name of this drug
Treatment SummaryUlobetasol is a powerful steroid used to treat severe plaque psoriasis and other skin conditions. It is closely related to clobetasol and was approved by the FDA in 1990.
Tazoracis the brand name
image of different drug pills on a surface
Duobrii Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Tazorac
Tazarotene
1997
29

Approved as Treatment by the FDA

Tazarotene, also known as Tazorac, is approved by the FDA for 9 uses including Lentigo and Acne Vulgaris .
Lentigo
Acne Vulgaris
Hypopigmentation
Psoriasis Vulgaris
Helps manage Psoriasis Vulgaris (Plaque Psoriasis)
mild Acne vulgaris
benign facial lentigines
Acne Vulgaris
facial fine wrinkling
facial hyperpigmentation

Effectiveness

How Duobrii Affects PatientsCorticosteroids, like Ulobetasol, work by blocking inflammation-causing signals and promoting anti-inflammatory signals. Ulobetasol needs to be applied once or twice each day, and the dose might be higher than the amount of corticosteroid hormones naturally produced by the body. It is important to remember that taking corticosteroids can lead to HPA axis suppression, which weakens the immune system, and increases the risk of infections.
How Duobrii works in the bodyCorticosteroids help reduce inflammation and swelling in the body. They do this by blocking certain molecules and proteins that help cause inflammation. They also reduce the number of white blood cells that rush to sites of inflammation. Low doses of corticosteroids reduce inflammation, while higher doses weaken your immune system. High doses of corticosteroids also increase your sodium levels and decrease your potassium levels.

When to interrupt dosage

The measure of Duobrii hinges upon the verified affliction, including Pruritus, corticosteroid responsive, Inflammatory Dermatosis and Plaque Psoriasis. The amount also varies based on the method of administration (e.g. Lotion - Topical or Cream) tabulated in the table below.
Condition
Dosage
Administration
Acne Vulgaris
, 0.001 mg/mg, 0.0005 mg/mg, 0.1 %, 0.05 %, 0.00045 mg/mg, 0.00005 mg/mg, 0.0001 mg/mg, 0.045 %
, Gel - Cutaneous, Cutaneous, Gel, Cream, Cream - Cutaneous, Oral, Gel - Oral, Topical, Gel - Topical, Cream - Topical, Aerosol, foam, Aerosol, foam - Topical, Lotion, Lotion - Topical
Hypopigmentation
, 0.001 mg/mg, 0.0005 mg/mg, 0.1 %, 0.05 %, 0.00045 mg/mg, 0.00005 mg/mg, 0.0001 mg/mg, 0.045 %
, Gel - Cutaneous, Cutaneous, Gel, Cream, Cream - Cutaneous, Oral, Gel - Oral, Topical, Gel - Topical, Cream - Topical, Aerosol, foam, Aerosol, foam - Topical, Lotion, Lotion - Topical
Lentigo
, 0.001 mg/mg, 0.0005 mg/mg, 0.1 %, 0.05 %, 0.00045 mg/mg, 0.00005 mg/mg, 0.0001 mg/mg, 0.045 %
, Gel - Cutaneous, Cutaneous, Gel, Cream, Cream - Cutaneous, Oral, Gel - Oral, Topical, Gel - Topical, Cream - Topical, Aerosol, foam, Aerosol, foam - Topical, Lotion, Lotion - Topical
facial hyperpigmentation
, 0.001 mg/mg, 0.0005 mg/mg, 0.1 %, 0.05 %, 0.00045 mg/mg, 0.00005 mg/mg, 0.0001 mg/mg, 0.045 %
, Gel - Cutaneous, Cutaneous, Gel, Cream, Cream - Cutaneous, Oral, Gel - Oral, Topical, Gel - Topical, Cream - Topical, Aerosol, foam, Aerosol, foam - Topical, Lotion, Lotion - Topical
facial fine wrinkling
, 0.001 mg/mg, 0.0005 mg/mg, 0.1 %, 0.05 %, 0.00045 mg/mg, 0.00005 mg/mg, 0.0001 mg/mg, 0.045 %
, Gel - Cutaneous, Cutaneous, Gel, Cream, Cream - Cutaneous, Oral, Gel - Oral, Topical, Gel - Topical, Cream - Topical, Aerosol, foam, Aerosol, foam - Topical, Lotion, Lotion - Topical
Acne Vulgaris
, 0.001 mg/mg, 0.0005 mg/mg, 0.1 %, 0.05 %, 0.00045 mg/mg, 0.00005 mg/mg, 0.0001 mg/mg, 0.045 %
, Gel - Cutaneous, Cutaneous, Gel, Cream, Cream - Cutaneous, Oral, Gel - Oral, Topical, Gel - Topical, Cream - Topical, Aerosol, foam, Aerosol, foam - Topical, Lotion, Lotion - Topical
Psoriasis Vulgaris
, 0.001 mg/mg, 0.0005 mg/mg, 0.1 %, 0.05 %, 0.00045 mg/mg, 0.00005 mg/mg, 0.0001 mg/mg, 0.045 %
, Gel - Cutaneous, Cutaneous, Gel, Cream, Cream - Cutaneous, Oral, Gel - Oral, Topical, Gel - Topical, Cream - Topical, Aerosol, foam, Aerosol, foam - Topical, Lotion, Lotion - Topical

Warnings

Duobrii has one contraindication and should not be employed when dealing with the conditions enumerated in the table below.There are 20 known major drug interactions with Duobrii.
Common Duobrii Drug Interactions
Drug Name
Risk Level
Description
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Tazarotene.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Tazarotene.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Tazarotene.
Clomocycline
Major
The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Clomocycline.
Demeclocycline
Major
The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Demeclocycline.
Duobrii Toxicity & Overdose RiskTaking too much of a glucocorticoid over a long period of time can lead to a number of health conditions, such as cataracts, glaucoma, high blood pressure, water retention, high cholesterol, ulcers, and even mental health issues like mood changes and psychosis. An overdose can be treated by reducing the dose or stopping the medication, as well as providing supportive care.
image of a doctor in a lab doing drug, clinical research

Duobrii Novel Uses: Which Conditions Have a Clinical Trial Featuring Duobrii?

18 active studies are currently examining the potential of Duobrii in alleviating Pruritus, Plaque Psoriasis and corticosteroid responsive Inflammatory Dermatoses.
Condition
Clinical Trials
Trial Phases
Lentigo
0 Actively Recruiting
Psoriasis Vulgaris
23 Actively Recruiting
Early Phase 1, Phase 3, Not Applicable, Phase 2, Phase 4, Phase 1
Acne Vulgaris
0 Actively Recruiting
Hypopigmentation
0 Actively Recruiting
facial hyperpigmentation
0 Actively Recruiting
facial fine wrinkling
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting

Duobrii Reviews: What are patients saying about Duobrii?

5Patient Review
12/2/2019
Duobrii for Plaque Psoriasis
I've been using this cream for a few weeks now and the results have been amazing. My biopsy site is the only thing that hasn't cleared up yet, but I'm hopeful that a few more weeks will do the trick.
5Patient Review
9/29/2019
Duobrii for Plaque Psoriasis
I've been using this cream for plaque psoriasis on my arms and legs, and it's working great! In just five days, I've seen a huge difference in the thickness of my psoriasis spots. They're redder now, but that's to be expected with any kind of treatment like this. My skin is peeling around the areas where I put the meds, but some lotion takes care of that.
5Patient Review
10/10/2019
Duobrii for Plaque Psoriasis
After using this for less than a week, the thick bumps on my skin were gone. I experienced some peeling and redness, but no pain, and my skin felt much smoother. So far, so good!
3Patient Review
10/2/2019
Duobrii for Plaque Psoriasis
I've only been using this product for a short while, so it's hard to tell if it's truly effective yet. So far, the results have been promising but I'm going to continue use and see how things go. The application process is straightforward which is great. My dermatologist didn't seem too familiar with the product, so that was a little frustrating; however, I reached out to the company directly and they were able to offer more guidance and support.
2.3Patient Review
5/1/2020
Duobrii for Plaque Psoriasis
This treatment worked great at first, but after a couple of weeks my skin became red and began to burn and itch. It's almost worse than the psoriasis itself. I have stopped using this cream. I can't say I wouldn't recommend it because it does work, but it really depends on how your body reacts to it.
2.3Patient Review
4/14/2020
Duobrii for Plaque Psoriasis
I was disappointed with this treatment. While it did help clear up a few spots, there were still several patches of skin that it did nothing for.
1.7Patient Review
12/20/2019
Duobrii for Plaque Psoriasis
While this drug did help with my plaque psoriasis at first, the skin irritation it caused was much worse than the psoriasis. Early on, I saw good results: clearer, smoother skin with only a little irritation that seemed to go away. But then, about three weeks in, the reaction got much worse. My skin became very red in more than half of the treatment area; itchy, irritated, and painful to touch in some areas. Consequently, I cannot recommend this experience or this drug.
1Patient Review
9/23/2019
Duobrii for Plaque Psoriasis
Though this cream helped to remove the scales of my psoriasis, it was very difficult to apply through my hair. After a few days of use, I developed an intense burning and itching sensation that forced me to discontinue use.
1Patient Review
8/30/2019
Duobrii for Plaque Psoriasis
I did not have a positive experience with this medication. My plaque psoriasis actually got worse, and I developed painful sunburn-like symptoms on the treated area. I also now have an infection. Overall, I would not recommend this treatment to others.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about duobrii

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long can you use Duobrii for?

"Subjects applying DUOBRII Lotion or the placebo lotion to all affected areas once daily for up to 8 weeks."

Answered by AI

What is Duobrii cream used for?

"DUOBRII is a prescription lotion that contains halobetasol propionate and tazarotene. It is used to treat adults with plaque psoriasis."

Answered by AI

Is Duobrii a steroid?

"Duobrii Lotion is a combination of halobetasol and tazarotene. Halobetasol is a highly potent steroid. Tazarotene is a retinoid."

Answered by AI

How long does Duobrii take to work?

"In just 8 weeks, you can see dramatic results that last for 12 weeks. Your skin will be almost clear, with only a few small patches of scales or redness remaining. The bumps and lumps caused by psoriasis will be barely noticeable."

Answered by AI

Clinical Trials for Duobrii

Have you considered Duobrii clinical trials? We made a collection of clinical trials featuring Duobrii, we think they might fit your search criteria.Go to Trials
Image of Lynderm Research in Markham, Canada.

ESK-001 for Plaque Psoriasis

18+
All Sexes
Markham, Canada
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study. Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis. Patients must consent and agree to: * ensure drug daily compliance until end of study or discontinuation. * visit the clinic for checkups and assessments. * provide blood and urine samples.
Phase 3
Recruiting
Quick Reply
Lynderm Research (+35 Sites)Alumis Inc
Image of Not posted in Webster, United States.

IRX4204 for Plaque Psoriasis

18+
All Sexes
Webster, TX
The goal of this clinical trial is to learn if IRX4204 works to treat plaque psoriasis in adults. It will also learn about the safety of IRX4204. The main questions it aims to answer are: * Does IRX4204 treat plaque psoriasis symptoms? * Does IRX4204 treat plaque psoriasis symptoms better than someone who is not being treated? * What medical problems do participants have when taking IRX4204? Researchers will compare IRX4204 to a placebo (a look-alike substance that contains no drug) to see if the drug works to treat mild to moderate plaque psoriasis. Participants will: * Take IRX4204 every day for 28 days * Visit the clinic once every week for checkups and tests * Complete specific assessments about plaque psoriasis and changes to plaques
Phase 2
Waitlist Available
Not postedIo Therapeutics
Have you considered Duobrii clinical trials? We made a collection of clinical trials featuring Duobrii, we think they might fit your search criteria.Go to Trials
Have you considered Duobrii clinical trials? We made a collection of clinical trials featuring Duobrii, we think they might fit your search criteria.Go to Trials